Alterations of the mTOR pathway in hepatic angiomyolipoma with emphasis on the epithelioid variant and loss of heterogeneity of TSC1/TSC2

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2559|66|5|695-705

ISSN： 0309-0167

Source： HISTOPATHOLOGY, Vol.66, Iss.5, 2015-04, pp. : 695-705

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The mTOR Pathway in Breast Cancer

By Hynes Nancy   Boulay Anne  

Journal of Mammary Gland Biology and Neoplasia, Vol. 11, Iss. 1, 2006-01 ,pp. : 53-61

Springer Publishing Company

Access to resources Recommend Favorite

Lack of efficacy of mTOR inhibitors and ACE pathway inhibitors as antifibrotic agents in evolving and established fibrosis in Mdr2−/− mice

By  

LIVER INTERNATIONAL (ELECTRONIC), Vol. 35, Iss. 4, 2015-04 ,pp. : 1451-1463

John Wiley & Sons Inc

Access to resources Recommend Favorite

mTOR

By Marin Philippe   Meffre Julie   Bockaert Joël  

Médecine/sciences, Vol. 29, Iss. 1, 2013-01 ,pp. : 28-30

Edp Sciences

Access to resources Recommend Favorite

Ruptured Hepatic Epithelioid Angiomyolipoma: A Case Report and Literature Review

By  

Case Reports in Oncology, Vol. 7, Iss. 2, 2014-05 ,pp. : 369-375

Karger

Access to resources Recommend Favorite

Dose‐level response rates of mtor inhibition in tuberous sclerosis complex (TSC) related subependymal giant cell astrocytoma (SEGA)

By  

PEDIATRIC BLOOD & CANCER (ELECTRONIC), Vol. 62, Iss. 10, 2015-10 ,pp. : 1754-1760

John Wiley & Sons Inc

Access to resources Recommend Favorite